Refuse-to-Accept / Refuse-to-File
What a definition is not
A definition is SPEQ’s plain-language decode of how a term is used in practice, cited to the documents that define it. It is a practitioner reference, not legal or regulatory advice, it does not replace the definition in the source, and where a regulator’s wording differs the regulator’s wording governs.
Refuse-to-Accept and Refuse-to-File are FDA’s administrative screening decisions that an application is too incomplete for substantive review to even begin — distinct from a scientific review deficiency. FDA screens a new submission against a completeness checklist shortly after receipt, and an application failing that screen is returned to the applicant before the review clock starts.
For NDAs, the mechanism is “refuse to file” under FDA’s filing review; for ANDAs it is “refuse to receive.” For 510(k) device submissions, FDA applies a non-regulatory Refuse to Accept policy using an acceptance checklist, screening for missing required elements — administrative information, a predicate comparison, or required testing summaries, for example — before the substantive review clock begins.
A refuse-to-file or refuse-to-accept decision is purely administrative: it says nothing about whether the underlying science is adequate, only that the submission as filed does not contain the elements FDA’s checklist requires to start a review. Applicants generally correct the identified gaps and resubmit rather than appeal the decision.
- —Administrative completeness screen, not a scientific review outcome
- —“Refuse to file” (NDA) and “refuse to receive” (ANDA) under 21 CFR 314.101
- —“Refuse to Accept” for 510(k)s is a guidance-based checklist policy, not a CFR requirement
- —Review clock does not start until the submission passes this screen
21 CFR 314.101 (NDA refuse-to-file; ANDA refuse-to-receive); FDA guidance “Refuse to Accept Policy for 510(k)s” (non-regulatory)
Frequently asked questions
What is Refuse-to-Accept / Refuse-to-File?
Refuse-to-Accept and Refuse-to-File are FDA’s administrative screening decisions that an application is too incomplete for substantive review to even begin — distinct from a scientific review deficiency. FDA screens a new submission against a completeness checklist shortly after receipt, and an application failing that screen is returned to the applicant before the review clock starts.
Which regulations cover Refuse-to-Accept / Refuse-to-File?
21 CFR 314.101 (NDA refuse-to-file; ANDA refuse-to-receive); FDA guidance “Refuse to Accept Policy for 510(k)s” (non-regulatory)